| 000 | 01810 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250518054237.0 | ||
| 264 | 0 | _c20200803 | |
| 008 | 202008s 0 0 eng d | ||
| 022 | _a1569-8041 | ||
| 024 | 7 |
_a10.1093/annonc/mdz270 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDe Vincentis, G | |
| 245 | 0 | 0 |
_aAdvances in targeted alpha therapy for prostate cancer. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _c11 2019 |
||
| 300 |
_a1728-1739 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aActinium |
| 650 | 0 | 4 |
_aAlpha Particles _xtherapeutic use |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 |
_aDipeptides _xpharmacology |
| 650 | 0 | 4 |
_aHeterocyclic Compounds, 1-Ring _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPrecision Medicine _xmethods |
| 650 | 0 | 4 | _aProgression-Free Survival |
| 650 | 0 | 4 |
_aProstate-Specific Antigen _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xgenetics |
| 650 | 0 | 4 |
_aRadioimmunotherapy _xadverse effects |
| 650 | 0 | 4 |
_aRadiopharmaceuticals _xpharmacology |
| 650 | 0 | 4 | _aRadiotherapy Planning, Computer-Assisted |
| 650 | 0 | 4 |
_aTumor Microenvironment _xdrug effects |
| 700 | 1 | _aGerritsen, W | |
| 700 | 1 | _aGschwend, J E | |
| 700 | 1 | _aHacker, M | |
| 700 | 1 | _aLewington, V | |
| 700 | 1 | _aO'Sullivan, J M | |
| 700 | 1 | _aOya, M | |
| 700 | 1 | _aPacilio, M | |
| 700 | 1 | _aParker, C | |
| 700 | 1 | _aShore, N | |
| 700 | 1 | _aSartor, O | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 30 _gno. 11 _gp. 1728-1739 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdz270 _zAvailable from publisher's website |
| 999 |
_c30011573 _d30011573 |
||